Nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation and injury, has emerged as one of major causes for end-stage liver disease like hepatocellular carcinoma. However, what drives its progression?
Aug 25, 2022
0
12
A longitudinal national study led by Virginia Commonwealth University researcher Arun Sanyal, M.D., shows that people with advanced liver scarring caused by obesity, diabetes and related disorders are dying of liver disease.
Oct 21, 2021
0
319
A type of fatty liver disease that commonly affects patients with HIV can be safely treated with vitamin E, a McGill-led study has found.
Feb 14, 2020
0
113
(HealthDay)—Mass spectrometry (MS)-based profiling combined with clinical variables can identify nonalcoholic steatohepatitis (NASH), according to a study published in the October issue of Clinical Gastroenterology and ...
Oct 6, 2016
0
0
Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...
Sep 21, 2016
0
25
(HealthDay)—A novel non-elective inpatient hepatology rotation increases knowledge of chronic liver disease (CLD) among internal medicine (IM) residents, according to a study published online Aug. 10 in Hepatology.
Sep 6, 2016
0
0
(HealthDay)—Weight loss can improve nonalcoholic steatohepatitis (NASH) in obese or overweight people, whether excess pounds are shed through lifestyle changes or weight-loss surgery, according to research published in ...
Aug 24, 2015
0
26
Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications ...
Jul 9, 2015
0
12
(HealthDay)—Nonalcoholic steatohepatitis (NASH)-associated changes in liver function affect kidney transporter expression and metformin pharmacokinetics, according to an experimental study published online May 27 in Diabetes ...
Jun 4, 2015
0
6
A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...
May 19, 2015
0
20
Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.
This text uses material from Wikipedia licensed under CC BY-SA
